You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ORAL THERAPEUTIC FOR INDUCING FETAL HEMOGLOBIN

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): Sickle cell disease (SCD) and beta-thalassemia are genetic disorders caused by molecular mutations affecting the genes for adult hemoglobin. With a world-wide birth prevalence of 2/1,000, hemoglobin disorders are the most common genetic diseases in the world (360,000 patients/year - 250,000 with sickling disorders and 110,000 with thalassemias. These conditions ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. ORAL THERAPEUTIC FOR INDUCING FETAL HEMOGLOBIN

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): Sickle cell disease (SCD) and beta-thalassemia are genetic disorders caused by molecular mutations affecting the genes for adult hemoglobin. With a world-wide birth prevalence of 2/1,000, hemoglobin disorders are the most common genetic diseases in the world (360,000 patients/year - 250,000 with sickling disorders and 110,000 with thalassemias. These conditions ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  3. ORAL THERAPEUTICS FOR VIRAL MALIGNANCIES

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human lymphoid malignancies and carcinomas for which there are presently few effective treatments. Each year in the U.S., there are approximately 27,000 people afflicted with diseases caused by the Epstein-Barr virus, and an additional 107,000 people afflicted with malignancies associated with the Epstein ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. ORAL THERAPEUTICS FOR VIRAL MALIGNANCIES

    SBC: Gene Regulation Laboratories            Topic: N/A

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human lymphoid malignancies and carcinomas for which there are presently few effective treatments. Each year in the U.S., there are approximately 27,000 people afflicted with diseases caused by the Epstein-Barr virus, and an additional 107,000 people afflicted with malignancies associated with the Epstein ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  5. CYTOTOXIC GONADOTROPIN RELEASING HORMONE DERIVATIVES

    SBC: GONEX, INC.            Topic: N/A

    Hormonally responsive cancers, such as prostate and breast, are a major cause of morbidity and mortality in the aging population in the United States. These cancers can be treated by sex steroid antagonists by these compounds are costly and mutational escape occurs. Recent innovative approaches have used hormonotoxins to specifically target the cancer cells. Several such approaches are already in ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  6. GRADIENT COILS TO ENHANCE MRI RESEARCH IN MENTAL HEALTH

    SBC: INSIGHT NEUROIMAGING SYSTEMS, LLC            Topic: N/A

    LONG RANGE OBJECTIVES To develop products that enhance research methods and applications in animal research using magnetic resonance imaging to study mental illness. PHASE I The planar gradient coil, or PROTOTYPE we propose to develop will optimize the working area inside MR spectrometers expanding the experimental applications and the types of animals that can be studied in small bore ultra-high ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. ANIMAL TESTING OF A BLOCKING ANTIBODY OF PCRV

    SBC: INTERMUNE PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This grant will determine the efficacy of a humanized monoclonal antibody in treating a lethal Pseudomonas-induced lung injury. We have shown that the airspace instillation of a strain of Pseudomonas aeruginosa that contains the type Il system predictably causes lung necrosis, sepsis and death (J Clin Invest 1999). We have also shown th ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  8. NOVEL BISPHOSPHONATES FOR BREAST CANCER THERAPY

    SBC: MBC Pharma, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Bisphosphonates are currently used as bone-specific palliative treatments for metastatic bone disease in multiple myeloma and breast cancer patients. However, bisphosphonate use has no proven impact on primary tumor burden and overall survival and only moderately reduces skeletal complications. Bisphosphonate conjugates were synthesized using proprietary techn ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. DEVELOPMENT OF STANDARDIZED MILK THISTLE PRODUCT

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (Provided by applicant): The objective of this Phase I and II fast track application is to develop a standardized milk thistle product and to assure a quality controlled and reliable source for future basic and clinical studies. Natural Pharmacia International, Inc, an established natural products laboratory, has established an excellent consortial team to establish a standardized milk ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  10. DEVELOPMENT OF STANDARDIZED MILK THISTLE PRODUCT

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (Provided by applicant): The objective of this Phase I and II fast track application is to develop a standardized milk thistle product and to assure a quality controlled and reliable source for future basic and clinical studies. Natural Pharmacia International, Inc, an established natural products laboratory, has established an excellent consortial team to establish a standardized milk ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government